Table 2.
Anti-Giardia activity of selected Pathogen Box compounds.
| Compound | Inhibition (%) |
Current study 48h IC50±SD (M) |
Previous study; 24h IC50±SD (M) | ||
|---|---|---|---|---|---|
| Current study (5 μM, 48h) | Previous study (16 μM, 24h) | Imaging | 3H-Thymidine incorporation | ||
| MMV676358 | 96.0 ± 2.6 | 90 ± 0 | 2.7 × 10−7±8.1 × 10−8 | 4.5 × 10−7±1.4 × 10−7 | Not assessed |
| MMV028694 |
95.4 ± 8.0 |
99 ± 0 |
9.1 × 10−7±2.3 × 10−7 |
1.9 × 10−6±4.0 × 10−8 |
3.9 × 10−6±1.3 × 10−6 |
| MMV688844 | 24.6 ± 9.7 | 98 ± 0 | >10 × 10−6 | >10 × 10−6 | 2.3 × 10−6±4.3 × 10−7 |
| MMV676395 | 13.8 ± 19.5 | 98 ± 0 | >10 × 10−6 | >10 × 10−6 | 1.6 × 10−6±2.0 × 10−7 |
| MMV495543 | 0.0 ± 0.0 | 97 ± 2 | >10 × 10−6 | Not assessed | 2.8 × 10−6±2.1 × 10−7 |
| MMV687800 clofazimine |
59.1 ± 34.5 |
97 ± 0 |
6.6 × 10−6±7.0 × 10−7 |
Not assessed |
1.8 × 10−6±2.3 × 10−7 |
| mebendazole | 94.9 ± 5.8 | 26 ± 0 | 5.0 × 10−8±7.0 × 10−9 | 1.6 × 10−7±9.0 × 10−8 | Not assessed; >1.6 × 10−5 |
| albendazole | 92.3 ± 8.1 | Not assessed | 9.0 × 10−8±2.0 × 10−8 | 1.7 × 10−7±4.0 × 10−8 | 4.1 × 10−7± |